Intelligence · Patents
Patents expiring in 2033
Annual patent cliff calendar for 2033 — US pharmaceutical patents by expiration date.
- Patents
- 1,330
Quick answer
1,330 indexed pharmaceutical patents have expiration dates in 2033. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 8476236
Treatment of skin conditions by Dickkopf1 (DKK1)
granted -
US 8476281
Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea
granted -
US 8476338
Dental curable composition and composite resin using the same
granted -
US 8476413
Sulfanyl-tetrahydropyran-based compounds and methods of their use
granted -
US 8474529
Control of concentric tubing direction
granted -
US 8476263
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
granted -
US 8476043
Inhibitors for the soluble epoxide hydrolase
granted -
US 8475828
Medical apparatus and method for producing same
granted -
US 8476229
Blood sugar-modulating polypeptides
granted -
US 8475792
Molecules with extended half-lives, compositions and uses thereof
granted -
US 8475764
Labelled adrenomedullin derivatives and their use for imaging and therapy
granted -
US 8476451
Tubulysin D analogues
granted -
US 8476442
Process for making modulators of cystic fibrosis transmembrane conductance regulator
granted -
MX 2013000877
APPLICATION OF β-FUNCTIONALIZED DIHYDROXY-CHLORINS FOR PDT.
granted -
US 8481731
Compounds, pharmaceutical composition and methods relating thereto
granted -
US 8481578
Thiophene-carboxamides useful as inhibitors of protein kinases
granted -
US 8481760
Inhibition and treatment of prostate cancer metastasis
granted -
US 8481289
Triple acting antimicrobials that are refractory to resistance development
granted -
US 8481044
Neprilysin inhibitors
granted -
US 8481035
Methods for treating chronic pelvic pain syndrome with antibodies that binds MCP-1 or MIP-1A
granted -
US 8481024
Vaccines against tularemia
granted -
US 8480995
Use of sodium selenosulfate for supplementing selenium and enhancing the therapeutic efficacy of chemotherapy agents, and a rapid process for preparing sodium selenosulfate
granted -
US 8481551
Gyrase and topoisomerase IV inhibitors
granted -
US 8481005
Methods to prevent cytotoxicity using N-acetyl-cysteine
granted -
US 8481569
Iminopyridine derivatives and use thereof
granted -
US 8481757
Compounds and compositions useful in the treatment of malaria
granted -
US 8481524
c-MET protein kinase inhibitors
granted -
US 8481313
Retinal pigment epithelial stem cells
granted -
US 8481521
Methods of treating cell proliferative disorders
granted -
US 8480637
Nanochanneled device and related methods
granted -
US 8481006
Melt formula
granted -
US 8481010
Covalently bonding nail primer
granted -
US 8481038
Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
granted -
US 8481046
VEGF antagonist formulations for intravitreal administration
granted -
US 8481048
Methods for preparing immunogenic conjugates
granted -
US 8481095
Method for anti-oxidation, inhibiting activity and/or expression of matrix metalloproteinase, and/or inhibiting phosporylation of mitogen-activated protein kinase using flemingia macrophylla extract
granted -
US 8481255
Scytovirin domain 1 related polypeptides
granted -
US 8481055
Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
granted -
US 8481311
Progenitor cells from wharton's jelly of human umbilical cord
granted -
US 8481483
Cyclosporin analogues
granted -
US 8481511
Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process
granted -
US 8481516
Ciclesonide containing sterile aqueous suspension
granted -
US 8481478
Method for automated, large-scale measurement of the molecular flux rates of the proteome or the organeome using mass spectrometry
granted -
US 8481507
Micro-RNAs that control myosin expression and myofiber identity
granted -
US 8481552
Solid forms of gyrase inhibitor (R)-1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-YL]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-YL]urea
granted -
US 8481529
Combination cancer chemotherapy
granted -
US 8481538
Heterocyclic inhibitors of c-Met and uses thereof
granted -
US 8481549
Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
granted
Frequently asked questions
How many pharma patents expire in 2033?
1,330 published patents in our USPTO index have expiration dates falling in calendar year 2033.